CytoMed Therapeutics Limited (NASDAQ:GDTC) Short Interest Update

CytoMed Therapeutics Limited (NASDAQ:GDTC) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 101,000 shares, a decrease of 21.0% from the February 28th total of 127,800 shares. Based on an average daily volume of 194,300 shares, the short-interest ratio is presently 0.5 days. Currently, 2.1% of the shares of the stock are short sold.

CytoMed Therapeutics Price Performance

Shares of NASDAQ:GDTC traded up $0.03 during midday trading on Wednesday, hitting $2.23. The company had a trading volume of 1,564 shares, compared to its average volume of 75,347. The business’s 50-day simple moving average is $2.62 and its 200-day simple moving average is $2.44. CytoMed Therapeutics has a twelve month low of $1.20 and a twelve month high of $4.05.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.